ZL-1201
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human
CD47
ZL-1201 (15 min) binds to CD47 on Jurkat cells[1].
ZL-1201 (10 μg/mL; 30 min) when combined with Trastuzumab (HY-P9907), Cetuximab (HY-P9905), or Rituximab (HY-P9913) significantly increases phagocytosis index compared to single agents or isotype control[1].
ZL-1201 (2 h) does not induce hemagglutination in whole blood[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice per week; 3–12 weeks
-
Result:Achieved >80% tumor growth inhibition (TGI) in Raji lymphoma xenografts; showed limited TGI (<50%) alone in solid tumor xenografts; significantly inhibited tumor growth when combined with therapeutic mAbs and chemotherapy, with triple combinations achieving maximal antitumor efficacy; increased intratumoral M1 macrophages, decreased M2 macrophages, and modulated cytokine release (increased TNFα/MCSF, decreased IL4) in the SKOV3 model
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
ZL-1201 関連分類
HY-P991927 関連分類
Powered by Bioz